#OncliveOnAir
LightNews LightNews
onclive.bsky.social
🎙️ In case you missed any, read a recap of the episodes of #OncliveOnAir that aired in September 2026. @lpetrillz.bsky.social @matthewkurianmd.bsky.social #oncology #hematology

Read the full recap ➡️: www.onclive.com/view/revisit...
Revisit Every OncLive On Air Episode From September 2026 | OncLive
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
www.onclive.com
October 1, 2026 at 9:37 PM
onclive.bsky.social
In our latest episode of #OncLiveOnAir, Dr Rachna Shroff of the University of Arizona Cancer Center discussed the SWOG S1815 trial of a triplet regimen in patients with newly diagnosed, advanced biliary tract cancer.
@rachnatshroff.bsky.social #oncology #podcast
www.onclive.com/view/triplet...
February 26, 2025 at 6:28 PM
ryancassaday.bsky.social
Thanks to staff of #OncLiveOnAir for the chance to discuss abstracts on ALL from #ASH24. @uwmedicine.bsky.social @fredhutch.bsky.social

www.onclive.com/view/blinatu...
Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.
www.onclive.com
January 25, 2025 at 3:49 PM
onclive.bsky.social
🎙️ On this episode of #OncLiveOnAir, @stolaney1.bsky.social discusses the @fda.gov approval of first-line sacituzumab govitecan plus pembrolizumab for locally advanced or metastatic PD-L1–positive TNBC. @danafarber.bsky.social @harvardmed.bsky.social #bcsm #oncology

www.onclive.com/view/fda-app...
July 28, 2026 at 6:07 AM
onclive.bsky.social
Revisit Every OncLive On Air Episode From June 2025
#podcast #OncLiveOnAir
www.onclive.com/view/revisit...
Revisit Every OncLive On Air Episode From June 2025
Read a recap of the episodes of OncLive On Air that debuted in June 2025.
www.onclive.com
July 1, 2025 at 8:09 PM
onclive.bsky.social
WATCH 📺: In this episode of #OncLiveOnAir 🎙️, Narjust Florez, MD, of @danafarber.bsky.social, and Jonathan Wesley Riess, MD, MS, of @ucdavis.bsky.social, discuss HER2 overexpression vs HER2 mutations in NSCLC. #lcsm #oncology

Watch or listen ➡️: www.onclive.com/view/recent-...
Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC | OncLive
Drs Florez and Riess discuss the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer.
www.onclive.com
September 25, 2026 at 12:03 AM
onclive.bsky.social
In this episode of #OncLiveOnAir 🎙️🎧, Onyee Chan, MD, of
@moffittnews.bsky.social, and Bradley D. Hunter, MD, of
Intermountain Healthcare, discuss evolving treatment strategies in chronic myeloid leukemia. Listen now: onclive.com/view/ascimin... #leusm #medtwitter #oncology
December 31, 2024 at 1:24 AM
onclive.bsky.social
🎙️ Time to tune in 🎧
In our latest episode of #OncLiveOnAir, Drs Mark B. Geyer of @mskcancercenter.bsky.social and Elias Jabbour of @mdanderson.bsky.social discussed the role of ponatinib in Ph+ ALL, efficacy data, and more.
LISTEN:
www.onclive.com/view/ponatin...

@markgeyermd.bsky.social #leusm
February 11, 2025 at 2:39 PM
onclive.bsky.social
🎙️On this episode of #OncLiveOnAir Philip A. Philip, MD, of @henryfordhealth.bsky.social discusses TTFields in pancreatic cancer and what phase 3 data has shown in locally advanced disease.

Listen here ➡️: www.onclive.com/view/explori...

#pancsm #oncology
Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer | OncLive
Philip A. Philip, MD, discusses TTFields in pancreatic cancer and what phase 3 data has shown in locally advanced disease.
www.onclive.com
September 28, 2026 at 5:38 PM
yalecancer.bsky.social
Dr. Anne Chiang recently joined On Air, the podcast from
@onclive.bsky.social , to discuss the rapidly evolving treatment landscape in small cell #lungcancer and what this new era of innovation means for patients.
🎧 onclive.com/view/integra...
#OncLiveOnAir #SCLC
Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD | OncLive
Anne Chiang, MD, PhD, discusses the rapidly evolving treatment landscape in SCLC and what this new era of innovation means for patients.
onclive.com
March 9, 2026 at 1:58 PM
onclive.bsky.social
🎙️ On this episode of #OncLiveOnAir, Tanios S. Bekaii-Saab, MD, discusses the current state of the metastatic colorectal cancer treatment landscape and potential future research directions. @mayoclinic.org @mayocliniccancer.bsky.social #crcsm #oncology

www.onclive.com/view/biomark...
July 30, 2026 at 9:21 PM
onclive.bsky.social
In the latest episode of #OncLiveOnAir, Chandler Park, MD, of Norton Cancer Institute, discusses the main regimens in the current frontline #BladderCancer treatment paradigm. 🎙️✨ #blcsm #podcasts #OncLive
www.onclive.com/view/compreh...
April 4, 2025 at 1:36 PM
onclive.bsky.social
In the latest episode of #OncLiveOnAir 🎙️, Drs Liliana Bustamante and Jessica Stine, of Florida Cancer Specialists & Research Institute, discuss their unique journeys toward choosing oncology careers and the importance of mentorship between colleagues.

🎧: www.onclive.com/view/peer-su...
April 11, 2025 at 11:01 PM
onclive.bsky.social
A new episode of #OncLiveOnAir 🎙️ has aired! Stacey A. Cohen, MD, of @fredhutch.bsky.social @uwmedicine.bsky.social, sheds light on the evolving role of circulating tumor DNA in clinical decision-making for patients with CRC. Listen now 🎧: onclive.com/view/the-evo... #crcsm #medtwitter #oncology
December 31, 2024 at 1:16 AM
onclive.bsky.social
🎙️On this episode of #OncLiveOnAir @jtrent.bsky.social of the Miami Miller School of Medicine discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.

Listen here ➡️: www.onclive.com/view/greater...

#scmsm #oncology
Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD | OncLive
Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.
www.onclive.com
August 7, 2026 at 7:04 PM
onclive.bsky.social
🎙️ On this episode of #OncLiveOnAir, Misty D. Shields, MD, PhD, @triparnasen.bsky.social, and Ditte Primdahl, MD, discuss the ties between cancer-associated LEMS and small cell lung cancer, diagnostic tips, and management strategies. #lcsm #oncology

www.onclive.com/view/experts...
July 29, 2026 at 9:52 PM
onclive.bsky.social
🎧 On this episode of #OncLiveOnAir, @ptarantinomd.bsky.social discusses practice-informing data regarding antibody-drug conjugates in breast cancer presented at #ASCO26. @danafarber.bsky.social @harvardmed.bsky.social @ascocancer.bsky.social #bcsm #oncology

www.onclive.com/view/asco-20...
July 28, 2026 at 8:36 PM
onclive.bsky.social
🎧 On this episode of #OncLiveOnAir, Jorge Cortes, MD, and Elias Jabbour, MD, discuss the orally disintegrating tablet formulation of nilotinib and its June 2026 @fda.gov approval for patients with CML. @mdanderson.bsky.social #leusm #hematology #oncology

www.onclive.com/view/fda-app...
July 28, 2026 at 1:00 AM
onclive.bsky.social
🎙️ NEW EPISODE: #OncLiveOnAir: In this episode, Neil Gross, MD, FACS, of @mdanderson.bsky.social, discusses:
🔑 Key biological differences between CSCC and BCC
🔑 Why resectability is the first branch point in treatment planning
🔑 The role of adjuvant cemiplimab
🎧 Listen now: hubs.li/Q04pWmLG0
Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS | OncLive
Dr Gross discusses the key biological and clinical distinctions between cutaneous squamous cell carcinoma and basal cell carcinoma.
hubs.li
July 17, 2026 at 5:07 PM
onclive.bsky.social
Revisit Every #OncLiveOnAir Episode From September 2025 #oncology

Read the full recap! ⬇️

www.onclive.com/view/revisit...
Revisit Every OncLive On Air Episode From September 2025 | OncLive
In case you missed any, below is a recap of every OncLive On Air episode that aired in September 2025.
www.onclive.com
October 1, 2025 at 6:37 PM
onclive.bsky.social
Revisit Every OncLive On Air Episode From March 2025
#OncLiveOnAir #Oncology #podcast
www.onclive.com/view/revisit...
Revisit Every OncLive On Air Episode From March 2025
Read a recap of the episodes of OncLive On Air that aired in March 2025.
www.onclive.com
April 2, 2025 at 7:54 PM
onclive.bsky.social
In case you missed it, read a recap of the episodes of #OncLiveOnAir that aired in February 2025!

www.onclive.com/view/revisit...
Revisit Every OncLive On Air Episode From February 2025
Read a recap of the episodes of OncLive On Air that aired in February 2025.
www.onclive.com
March 3, 2025 at 2:39 PM
onclive.bsky.social
In today’s episode of #OncLiveOnAir, Christopher L. Moertel, MD, discusses the significance of the FDA approval of mirdametinib, based on efficacy and safety data from the phase 2 ReNeu trial.

LISTEN: www.onclive.com/view/da-appr...

#oncology #MedEd
February 20, 2025 at 11:01 PM
onclive.bsky.social
⭐️ NEW PODCAST DROPPED ⭐️

In our latest episode of #OncLiveOnAir, Dr Aditya Bardia of the UCLA Health Jonsson Comprehensive Cancer Center
discussed the January 2025 #FDAapproval of Dato-DXd for HR–positive, HER2-negative breast cancer.

🎧 LISTEN 🎧:
www.onclive.com/view/fda-app...

#FDA #BCSM #podcast
February 14, 2025 at 4:05 PM
onclive.bsky.social
In this episode of #OncLiveOnAir, Ryan Cassaday, MD, of Fred Hutch provides insight on several trials assessing blinatumomab in B-cell acute lymphoblastic leukemia.
#leusm #hematology
LISTEN: www.onclive.com/view/blinatu...
January 24, 2025 at 5:10 PM